Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Gaseous Nitric Oxide for MRSA-Positive Ulcers
2008-001287-36Phase 2Terminated
- Sponsor
- Nitric BioTherapeutics
- Start
- Mar 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nitric oxide in Cutaneous ulcer and Staphylococcus aureus infection, sponsored by Nitric BioTherapeutics. Primary endpoint: Microbiological reduction. Started Mar 2008; status: terminated.
02
Drugs
nitric oxide
03
Conditions
Cutaneous ulcerStaphylococcus aureus infection
Beyond the preview
Go deeper on 2008-001287-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001287-36.